Edition: Global  
One News Page
“Probably the fastest-access news portal in the world”
> >

Alexion Pharmaceuticals Inc. Bottom Line Advances 20% In Q4

FinanzNachrichten.de Thursday, 16 February 2017
WASHINGTON (dpa-AFX) - Alexion Pharmaceuticals Inc. (ALXN) announced a profit for its fourth quarter that increased compared to the same period last year.The company said its bottom line totaled $...
0
shares
Share on
Facebook
Share on
Twitter
Post on 
Reddit
Share by
Email
 
Source: Market News Video - < > Embed

News video: S&P 500 Analyst Moves: ALXN

S&P 500 Analyst Moves: ALXN 01:19

The latest tally of analyst opinions from the major brokerage houses shows that among the components of the S&P 500 index, Alexion Pharmaceuticals (ALXN) is now the #98 analyst pick, moving up by 3 spots. This rank is formed by averaging the analyst opinions for each component from each broker, and...

You Might Like


Recent related news

Darden Restaurants Inc. Bottom Line Climbs 6% In Q4

WASHINGTON (dpa-AFX) - Darden Restaurants Inc. (DRI) revealed earnings for its fourth quarter that gained ground from last year.The company said its bottom line...
FinanzNachrichten.de - Markets

AVEO Pharmaceuticals shares flying as its kidney cancer drug makes headway

AVEO Pharmaceuticals Inc (NASDAQ: AVEO) raced up 77% as its cancer drug was recommended for approval in Europe. The drug called Tivozanib is being licensed in...
Proactive Investors - Business


Other recent news in Markets

CBO Says 22 MILLION More Uninsured Under Senate Bill, Premiums Initially 20% Higher Then 30% LowerApple Responds To GOOGLE-Avis, Announces Deal With Hertz To "Manage Autonomous Fleet"
Liberals Get in Here and Redpill Me on Why Trump's TRAVEL BAN is Bad for AmericaGOP Leadership To Health-Care Holdouts: "Do You Really Want To Be Remembered For Saving Obamacare?"
White House Accuses Syria Of Planning Another Chemical Attack, Warns "Will Pay HEAVY PRICE"MIRANDA KERR Hands Over $8.1 Million in Jewelry to Justice Department
Three Day Programme: Drafting Commercial Contracts for the Pharmaceutical Industry (London, UNITED KINGDOM - November 20-21-22, 2017) - Research and MarketsThe Malaysian STOCK MARKET’s Equivalent Of Singapore-Listed Companies
GOOGLE HIT By $2.7 Bln EU Fine In Antitrust RulingSanofi Announces Approval of Kevzara® (sarilumab) to Treat Adult Patients with Moderately to Severely Active Rheumatoid Arthritis (RA) in the EUROPEAN UNION

Twitter

Environmentally friendly: One News Page is hosted on servers powered solely by renewable energy
© 2017 One News Page Ltd. All Rights Reserved.  |  About us  |  Disclaimer  |  Press Room  |  Terms & Conditions  |  Privacy Policy  |  Content Accreditation
 RSS  |  News for my Website  |  Free news search widget  |  Help  |  Contact us  |  DMCA / Content Removal
How are we doing? Send us your feedback  |   LIKE us on Facebook   FOLLOW us on Twitter   FIND us on Google+